Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remibrutinib in Moderate to Severe Hidradenitis Suppurativa
NCT06840392Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of remibrutinib in hidradenitis suppurativa (HS), sponsored by Novartis. Started Mar 2025; status: active, not recruiting.
02
Drugs
remibrutinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06840392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06840392.